Asset profile

Daratumumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved — Multiple Myeloma

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

Featured trials

Research

Unlock featured-trial analysis

Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.

Upcoming events

(76 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (14)

August 2026 (1)

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2026-08-31 · NCT04933539 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2026 (3)

Phase 2Lupus NephritisActive not recruiting

Est. primary completion 2026-09 · NCT04868838 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Plasma Cell MyelomaActive not recruiting

Est. primary completion 2026-09-29 · NCT05392946 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2026-09-30 · NCT06169215 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2026 (5)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2026-10 · NCT06083922 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2026-10 · NCT03004287 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaActive not recruiting

Est. primary completion 2026-10-07 · NCT03993912 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2026-10-20 · NCT06140966 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Multiple MyelomaNot yet recruiting

Est. primary completion 2026-10-31 · NCT05581875 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2026 (3)

Phase 1/2Multiple MyelomaRecruiting

Est. primary completion 2026-11 · NCT04973605 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2026-11 · NCT06505369 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Multiple MyelomaActive not recruiting

Est. primary completion 2026-11-30 · NCT03989414 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (2)

Phase 2Myeloma, MultipleActive not recruiting

Est. primary completion 2026-12 · NCT04009109 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaNot yet recruiting

Est. primary completion 2026-12-31 · NCT07764861 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (21)

January 2027 (1)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2027-01 · NCT06827860 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2027 (3)

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2027-02-01 · NCT07085728 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2027-02-01 · NCT04268498 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2027-02-26 · NCT04133636 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2027 (2)

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2027-03 · NCT04166565 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Multiple MyelomaRecruiting

Est. primary completion 2027-03-31 · NCT04068597 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (1)

Phase 1/2Multiple MyelomaRecruiting

Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (2)

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2027-05 · NCT04176718 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Plasma Cell Myeloma, Secondary AmyloidosisActive not recruiting

Est. primary completion 2027-05-17 · NCT03346135 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (1)

Phase 2Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2027-06 · NCT06015724 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2027 (3)

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2027-07 · NCT03556332 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2027-07-01 · NCT04124497 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaActive not recruiting

Est. primary completion 2027-07-30 · NCT05455320 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (1)

Phase 2Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaActive not recruiting

Est. primary completion 2027-10-30 · NCT03763162 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (3)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2027-11 · NCT07018050 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2027-11-15 · NCT06952478 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaActive not recruiting

Est. primary completion 2027-11-16 · NCT04975997 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (4)

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2027-12-20 · NCT04775550 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2027-12-30 · NCT06615479 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2027-12-31 · NCT06107738 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell MyelomaRecruiting

Est. primary completion 2027-12-31 · NCT04566328 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (9)

February 2028 (1)

Phase 2Multiple MyelomaNot yet recruiting

Est. primary completion 2028-02-28 · NCT06948084 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (1)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2028-03-31 · NCT07045909 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2028 (1)

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2028-04-26 · NCT06353022 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2028 (1)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2028-05 · NCT07485647 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2028 (2)

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2028-07 · NCT07742215 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2028-07-30 · NCT07638683 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (1)

Phase 1/2Multiple MyelomaActive not recruiting

Est. primary completion 2028-08 · NCT05434689 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (1)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2028-09-15 · NCT05695508 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (1)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2028-12-31 · NCT06100237 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (10)

January 2029 (3)

Phase 2Primary Plasma Cell LeukemiaRecruiting

Est. primary completion 2029-01-05 · NCT06636552 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2029-01-11 · NCT07764978 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaActive not recruiting

Est. primary completion 2029-01-31 · NCT05438043 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2029 (1)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2029-03-01 · NCT05896228 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2029 (1)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2029-04 · NCT07107529 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2029 (1)

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2029-05-21 · NCT07222761 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2029 (1)

Phase 3Multiple MyelomaActive not recruiting

Est. primary completion 2029-07-01 · NCT04071457 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2029 (1)

Phase 1/2Multiple MyelomaNot yet recruiting

Est. primary completion 2029-10-30 · NCT07681596 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2029 (2)

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2029-12 · NCT05527340 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Smoldering Plasma Cell MyelomaRecruiting

Est. primary completion 2029-12-31 · NCT03937635 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (6)

April 2030 (1)

Phase 2Multiple MyelomaNot yet recruiting

Est. primary completion 2030-04-01 · NCT07029776 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2030 (2)

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2030-09-02 · NCT06577025 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaNot yet recruiting

Est. primary completion 2030-09-04 · NCT07665450 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2030 (1)

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2030-10-18 · NCT05623020 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2030 (2)

Phase 1/2Multiple MyelomaRecruiting

Est. primary completion 2030-12 · NCT06953960 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaNot yet recruiting

Est. primary completion 2030-12-01 · NCT07247097 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (7)

January 2031 (1)

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2031-01 · NCT06187441 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2031 (1)

Phase 3Multiple MyelomaNot yet recruiting

Est. primary completion 2031-02-14 · NCT07671287 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2031 (2)

Phase 1/2Multiple MyelomaRecruiting

Est. primary completion 2031-04-01 · NCT06785415 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2031-04-30 · NCT05552222 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2031 (2)

Phase 2Multiple MyelomaActive not recruiting

Est. primary completion 2031-05 · NCT03314181 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Plasma Cell MyelomaRecruiting

Est. primary completion 2031-05-30 · NCT05561387 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2031 (1)

Phase 2/3Multiple MyelomaRecruiting

Est. primary completion 2031-06-01 · NCT04513639 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (2)

November 2032 (2)

Phase 2Multiple MyelomaRecruiting

Est. primary completion 2032-11 · NCT06974786 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Plasma Cell LeukemiaRecruiting

Est. primary completion 2032-11-06 · NCT07605416 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2033 (2)

June 2033 (2)

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2033-06 · NCT07649525 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaActive not recruiting

Est. primary completion 2033-06 · NCT05257083 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2034 (1)

August 2034 (1)

Phase 2Lymphoma, Primary EffusionRecruiting

Est. primary completion 2034-08-01 · NCT05907759 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2035 (1)

December 2035 (1)

Phase 1/2Multiple MyelomaRecruiting

Est. primary completion 2035-12 · NCT06892522 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2036 (2)

May 2036 (1)

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2036-05 · NCT06918002 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2036 (1)

Phase 3Multiple MyelomaRecruiting

Est. primary completion 2036-12 · NCT06932562 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2042 (1)

January 2042 (1)

Phase 2/3Multiple MyelomaRecruiting

Est. primary completion 2042-01 · NCT07095452 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.